Blood-group

The discovery in 1900 of the existence of blood groups, together with improved understanding of the importance of sterile conditions, paved the way to modem blood transfusion therapy. In 1915, the feasibiUty of storage of whole blood was demonstrated. During World War I, the optimal concentration of citrate for use as an anticoagulant was determined. This anticoagulant was used until 1942, when the acid—citrate—dextrose (ACD) solution was developed. 

Contamination of blood products with lymphocytes can lead to transfusion-induced reactions ranging from a mild fever to severe reactions such as alloimmunization and graft versus host disease (GvHD), in which the transfused lymphocytes (graft) survive the defensive immune reaction of the patient (host) and start a reaction which destroys the cells of the host. The patient also may develop an immune response to the human leukocyte antigen (HLA) type of the graft s cells and reject all platelet transfusions that do not match their own HLA system. The HLA system, found on blood platelets and lymphocytes, is more compHcated than, but similar to, the ABO blood group system of red cells. 

Transfusion-induced autoimmune disease has been a significant complication in the treatment of patients who require multiple platelet transfusions. Platelets and lymphocytes carry their own blood group system, ie, the human leukocyte antigen (HLA) system, and it can be difficult to find an HLA matched donor. A mismatched platelet transfusion does not induce immediate adverse reactions, but may cause the patient to become refractory to the HLA type of the transfused platelets. The next time platelets with an HLA type similar to that of the transfused platelets are transfused, they are rejected by the patient and thus have no clinical efficacy. Exposure to platelets originating from different donors is minimized by the use of apheresis platelets. One transfusable dose (unit) of apheresis platelets contains 3-5 x 10 platelets. An equal dose of platelets from whole blood donation requires platelets from six to eight units of whole blood. Furthermore, platelets can be donated every 10 days, versus 10 weeks for whole blood donations. 

It has been known for more than a century that human blood can be classified into four blood-group types (A, B, AB, and 0) and that blood from a donor of one type can t be transfused into a recipient with another type unless the two types are compatible (Table 25.1). Should an incompatible mix be made, the red blood cells clump together, or agglutinate. 

Figure 25.12 Structures of the A, B, and 0 blood-group antigenic determinants.

Immobilization of A and B blood group oligosaccharide haptens and preparation of immunoadsorbents with specificity to anti-A and anti-B antibodies has been carried out with the use of poly acrylate-coated PG (WPG-PA) [124]. Prespacered A and B-trisaccharide-fl-aminopropylglycosides were used for the synthesis. WPG-PA (1 g) quantitatively binds both haptens (2 pinole) whereas some other activated affinity supports (for example, CNBr-Sepharose 4B) do not. On the other hand, glycidoxypropyl-silica binds prespacered haptens completely but these materials reveal no specific adsorptivity. 

Biologicals. Figure 1 The ABO blood group system with immunochemical specificity due to terminal sugars and reciprocal antibodies in the serum. From Immunity Immune Response in Inflammatory Disease by DeFranco, Locksley and Robertson [2]. 

KELL blood group antigen is a plasma membrane protein isolated from red cells homologous to zinc-binding glycoproteins with neutral endopeptidase activity. 

Chemistry of Tissues. 2. Polysaccharides Showing Blood Group A Specificity and the Nature of the Constituent Units of the Stable Carbohydrate Residue of the A Substance from Pepsin, H. G. Bray, H. H. Henry, and M. Stacey, Biochem. J., 40 (1946) 124-130. 

Terms designating branches should be enclosed in square brackets. In a branched chain, the longest chain is regarded as the parent. If two chains are of equal length the one with lower Iocants at the branch point is preferred, although some oligosaccharides are traditionally depicted otherwise, such as the blood group A trisaccharide exemplified below. 

Different conformity assessment options are available, depending on the type of device and the level of associated risk. For lotv-risk devices, the manufacturer can make a declaration of conformity based solely on self-assessment, without the need for the involvement of a Notified Body. For all other devices Notified Bodies are required to perform one or more of the tasks outlined in Table 10.2. HIV and hepatitis tests and blood grouping tests represent the highest risk devices, as they are critical to ensuring the safety of blood and blood products. For example, a defective HIV test device could result in widespread infection in an unsuspecting population, whereas the detrimental effects ofan AIMD or a Class III device failure will just be confined to the individuals treated by the device. At this end of the risk spectrum. Notified Bodies are required to verify the applied quality system, the specific device design, and the... 

To study the binding mode of the yS-D-galactopyranosyl residue of the Lewis b human blood-group determinant to its monoclonal antibody or to a lectin, methyl 2-acetamido-2-deoxy-3-0-(6-deoxy-6-fluoro-2-0-a-L-fuco-pyranosyl-y -D-galactopyranosyl)-4-0-a-L-fucopyranosyl-/ -D-glucopyrano-side was synthesized. ... 

Glycosphingolipids are constituents of the outer leaflet of plasma membranes and are important in cell adhesion and cell recognition. Some are antigens, eg, ABO blood group substances. Certain gangliosides function as receptors for bacterial toxins (eg, for cholera toxin, which subsequently activates adenylyl cyclase). 

Glycosphingolipids (GSLs) (neutral GSLs, gangliosides, and complex species, including the ABO blood group substances) constitute about 5-10% of the total lipid. 

THE BIOCHEMICAL BASES OF THE ABO BLOOD GROUP SYSTEM HAVE BEEN ESTABLISHED... 

---